(5-Cyano-thiophen-2-ylmethyl)-carbamic acid tert-butyl ester | 302341-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (5-Cyano-thiophen-2-ylmethyl)-carbamic acid tert-butyl ester
• 英文别名: tert-Butyl ((5-cyanothiophen-2-yl)methyl)carbamate；tert-butyl N-[(5-cyanothiophen-2-yl)methyl]carbamate
• CAS: 302341-67-9
• 化学式: C₁₁H₁₄N₂O₂S
• 分子量: 238.31
• InChiKey: DXUXBZDPVIIKBO-UHFFFAOYSA-N

物化性质

• 沸点：
  386.8±32.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  90.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-Cyano-thiophen-2-ylmethyl)-carbamic acid tert-butyl ester 在 N-甲基吗啉 、 盐酸羟胺 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 [5-(N-Propoxy-carbamimidoyl)-thiophen-2-ylmethyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Novel, Potent Non-Covalent Thrombin Inhibitors Incorporating P3-Lactam Scaffolds

  摘要：

  Evolution of P-1-argininal inhibitor prototypes led to a series of non-covalent P-3-7-membered lactam inhibitors 1a-w, featuring novel peptidomimetic units that probe each of the S-1, S-2, and S-3 specificity pockets of thrombin. Rigid P-1-arginine surrogates possessing a wide range of basicity (calcd pK(a)'ssimilar toneutral-14) were surveyed. The design, synthesis, and biological activity of these targets are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00010-0
• 作为产物：
  描述：

  5-甲基-2-噻吩甲腈 在 N-溴代丁二酰亚胺(NBS) 、 sodium azide 、 偶氮二异丁腈 、 potassium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 四氯化碳 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 (5-Cyano-thiophen-2-ylmethyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Novel, Potent Non-Covalent Thrombin Inhibitors Incorporating P3-Lactam Scaffolds

  摘要：

  Evolution of P-1-argininal inhibitor prototypes led to a series of non-covalent P-3-7-membered lactam inhibitors 1a-w, featuring novel peptidomimetic units that probe each of the S-1, S-2, and S-3 specificity pockets of thrombin. Rigid P-1-arginine surrogates possessing a wide range of basicity (calcd pK(a)'ssimilar toneutral-14) were surveyed. The design, synthesis, and biological activity of these targets are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00010-0

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES MÉDIÉS PAR LE COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2020198062A1

  公开（公告）日：2020-10-01

  This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

  这份披露提供了用于治疗医学疾病的药物化合物，例如包括补体介导的疾病在内的补体Cl-介导的疾病。
• Non-covalent inhibitors of urokinase and blood vessel formation
  申请人：Corvas International, Inc.

  公开号：US20020037857A1

  公开（公告）日：2002-03-28

  Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

  提供了一种具有作为尿激酶非共价抑制剂活性并在减少或抑制血管形成方面具有活性的新化合物。这些化合物具有Pi基团，其中含有一个酰胺基团或鸟胺基团或其衍生物。这些化合物在体外用于监测纤溶酶原激活剂水平，在体内用于治疗通过抑制尿激酶或降低其活性而得到改善的病症，以及用于治疗血管形成与病理病变相关的病理状况。
• Dihydrothienopyrimidines for the Treatment of Inflammatory Diseases
  申请人：Pouzet Pascale

  公开号：US20080096882A1

  公开（公告）日：2008-04-24

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  该发明涉及公式1的新二氢噻吡嘧啶，以及其药理学上可接受的盐、对映体、旋光异构体、消旋体、水合物或溶剂合物，其中X为SO或SO2，但最好为SO，R1、R2和R3在描述中给出的含义，并且适用于治疗呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的药物组合物。
• Thrombin inhibitors having a lactam at P3
  申请人：Corvas International, Inc.

  公开号：US06541467B1

  公开（公告）日：2003-04-01

  The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.

  本发明提供了化合物，其在P3处具有内酰胺环，在P1处具有一个六元杂环，其中有两个环氮原子和其余环原子为碳原子。这些化合物具有生物活性，作为凝血酶的活性和有效的抑制剂。还描述了这些化合物的药学上可接受的盐，其制剂以及使用这些化合物和包含这些化合物的制剂作为治疗哺乳动物中的疾病状态的治疗剂的方法。这些疾病状态以异常血栓形成为特征。
• Dihydrothienopyrimidines for the treatment of inflammatory Diseases
  申请人：POUZET Pascale

  公开号：US20120108534A1

  公开（公告）日：2012-05-03

  The invention relates to new dihydrothienopyrimidine of formula 1 , as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  本发明涉及一种新的二氢噻唑嘧啶化合物，其化学式为1，以及其药物学上可接受的盐、对映异构体、对映体、外消旋体、水合物或溶剂化物，其中X为SO或SO2，但优选为SO，R1、R2和R3在说明中给出了其含义，该化合物适用于治疗呼吸或胃肠道不适或疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症，以及含有这些化合物的制药组合物。